Advertisement

Labormedizin pp 393-467 | Cite as

Endokrinologische Labordiagnostik

  • B. Obermayer-Pietsch
Chapter
  • 5.5k Downloads

Auszug

Die Labordiagnostik in der Endokrinologie erweitert sich laufend mit dem Nachweis neuer Hormone, Prohormone und Stoffwechselsubstanzen (z.B. Ghrelin, Cartilaps) und der Verfeinerung spezifischer Methoden zur Analyse von z.B. nicht eiweißgebundenen Fraktionen (z.B. fT3, fT4) oder Subfraktionen von Hormon- und Stoffwechselprodukten (z.B. Parathormon mit unterschiedlicher Moleküllänge und -funktion, Serum-Crosslaps).

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Allgemein

  1. Löffler G (2008) Basiswissen Biochemie mit Pathobiochemie. 7. Aufl. Springer Berlin, Heidelberg, New YorkGoogle Scholar
  2. Thomas L (2007) Labor und Diagnose. 7. Aufl. TH-Books Verlagsgesellschaft mbH, Frankfurt/MainGoogle Scholar

Speziell

  1. 1.
    Schimmel M, Utiger RD (1977) Thyroidal and peripheral production of thyroid hormones. Review of recent findings and their clinical implications. Ann Intern Med 87(6): 760–768PubMedGoogle Scholar
  2. 2.
    Leboulleux S, Baudin E, Travagli JP, Schlumberger M (2004) Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61(3): 299–310Google Scholar
  3. 3.
    Whitley RJ, Ain KB (2004) Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin Lab Med.; 24(1):29–47.PubMedGoogle Scholar
  4. 4.
    Derwahl M, Studer H. Nodular goiter and goiter nodules: Where iodine deficiency falls short of explaining the facts. Exp Clin Endocrinol Diabetes. 2001;109(5):250–260.PubMedGoogle Scholar
  5. 5.
    Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab. 1997; 82(5): 1589–1593.PubMedGoogle Scholar
  6. 6.
    Chadwick DR, Harrison BJ. The role of fine-needle aspiration cytology and frozen section histology in management of differentiated thyroid cancer: the UK experience. Langenbecks Arch Surg. 1998; 383(2):164–166.PubMedGoogle Scholar
  7. 7.
    Cooper DS. Antithyroid drugs. N Engl J Med. 2005; 352(9):905–917.PubMedGoogle Scholar
  8. 8.
    Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol. 2005; 152(1):1–9.PubMedGoogle Scholar
  9. 9.
    McLachlan SM, Rapoport B. Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies? Thyroid. 2004; 14(7):510–520.PubMedGoogle Scholar
  10. 10.
    Boulos PR, Hardy I. Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review. Curr Opin Ophthalmol. 2004; 15(5):389–400.PubMedGoogle Scholar
  11. 11.
    Danzi S, Klein I. Thyroid hormone and the cardiovascular system. Minerva Endocrinol. 2004; 29(3):139–150.PubMedGoogle Scholar
  12. 12.
    Meyer-Gessner M, Benker G, Lederbogen S, Olbricht T, Reinwein D. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest. 1994; 17(1):29–36.PubMedGoogle Scholar
  13. 13.
    Cooper DS. Hyperthyroidism. Lancet. 2003; 362(9382):459–468.PubMedGoogle Scholar
  14. 14.
    Rehman HU, Bajwa TA. Newly diagnosed hypothyroidism. BMJ. 2004; 329(7477):1271.PubMedGoogle Scholar
  15. 15.
    Gruters A, Krude H, Biebermann H. Molecular genetic defects in congenital hypothyroidism. Eur J Endocrinol. 2004; 151Suppl 3:U39–U44.PubMedGoogle Scholar
  16. 16.
    Stockigt JR. Case finding and screening strategies for thyroid dysfunction. Clin Chim Acta. 2002; 315(1–2):111–124.PubMedGoogle Scholar
  17. 17.
    Pittman JG. Evaluation of patients with mildly abnormal thyroid function tests. Am Fam Physician. 1996; 54(3):961–966.PubMedGoogle Scholar
  18. 18.
    Vitti P, Rago T. Thyroid ultrasound as a predicator of thyroid disease. J Endocrinol Invest. 2003; 26(7):686–689.PubMedGoogle Scholar
  19. 19.
    Wiersinga WM. Thyroid hormone replacement therapy. Horm Res. 2001; 56Suppl 1:74–81.PubMedGoogle Scholar
  20. 20.
    Marcocci C, Marino M, Rocchi R, Menconi F, Morabito E, Pinchera A. Novel aspects of immunosuppressive and radiotherapy management of Graves’ ophthalmopathy. J Endocrinol Invest. 2004; 27(3):272–280.PubMedGoogle Scholar
  21. 21.
    Su DH, Huang TS. Acute suppurative thyroiditis caused by Salmonella typhimurium: a case report and review of the literature. Thyroid. 2002; 12(11):1023–1027.PubMedGoogle Scholar
  22. 22.
    Klima G, Beranek M, Rothlauer W. Definite distinction between thyroidal inflammatory conditions and other soft tissue inflammations of the neck using ultrasound. Acta Med Austriaca. 1996; 23(1–2):80–82.PubMedGoogle Scholar
  23. 23.
    Slatosky J, Shipton B, Wahba H. Thyroiditis: differential diagnosis and management. Am Fam Physician. 2000; 61(4):1047–1052.PubMedGoogle Scholar
  24. 24.
    Lazarus JH. Thyroid disorders associated with pregnancy: etiology, diagnosis, and management. Treat Endocrinol. 2005; 4(1):31–41.PubMedGoogle Scholar
  25. 25.
    Chang TC, Lai SM, Wen CY, Hsiao YL. Three-dimensional cytomorphology in fine needle aspiration biopsy of subacute thyroiditis. Acta Cytol. 2004; 48(2):155–160.PubMedGoogle Scholar
  26. 26.
    Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann I ntern Med. 2005; 142(11):926–931.Google Scholar
  27. 27.
    Fernandes JK, Day TA, Richardson MS, Sharma AK. Overview of the management of differentiated thyroid cancer. Curr Treat Options Oncol. 2005; 6(1):47–57.PubMedGoogle Scholar
  28. 28.
    Zimmermann MB. Assessing iodine status and monitoring progress of iodized salt programs. J Nutr. 2004 Jul;134(7):1673–1677.Google Scholar
  29. 29.
    Brauckhoff M, Lorenz K, Ukkat J, Brauckhoff K, Gimm O, Dralle H. Medullary thyroid carcinoma. Scand J Surg. 2004; 93(4):249–260.PubMedGoogle Scholar
  30. 30.
    Stathatos N, Wartofsky L. The euthyroid sick syndrome: is there a physiologic rationale for thyroid hormone treatment? J Endocrinol Invest. 2003; 26(12):1174–1179.PubMedGoogle Scholar
  31. 31.
    Lazarus JH, Premawardhana LD. Screening for thyroid disease in pregnancy. J Clin Pathol. 2005; 58(5):449–452.PubMedGoogle Scholar
  32. 32.
    Redmond GP. Thyroid dysfunction and women’s reproductive health. Thyroid. 2004; 14Suppl 1:S5–S15.PubMedGoogle Scholar
  33. 33.
    Allahabadia A, Weetman AP. Dynamic thyroid stimulating hormone tests: do they still have a role? J Endocrinol Invest. 2003; 26(7 Suppl):31–38.PubMedGoogle Scholar
  34. 34.
    Gunn IR, Gaffney D. Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann Clin Biochem. 2004; 41(Pt 6):441–458.PubMedGoogle Scholar
  35. 35.
    Levine MA, Germain-Lee E, Jan de Beur S. Genetic basis for resistance to parathyroid hormone. Horm Res. 2003; 60Suppl 3:87–95.PubMedGoogle Scholar
  36. 36.
    Hershkovitz E, Parvari R, Diaz GA, Gorodischer R. Hypoparathyroidism-retardation-Dysmorphism (HRD) syndrome—a review. J Pediatr Endocrinol Metab. 2004; 17(12):1583–1590.PubMedGoogle Scholar
  37. 37.
    Pattou F, Combemale F, Fabre S, Carnaille B, Decoulx M, Wemeau JL, Racadot A, Proye C. Hypocalcemia following thyroid surgery: incidence and prediction of outcome. World J Surg. 1998; 22(7):718–724.PubMedGoogle Scholar
  38. 38.
    Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med. 2005; 257(1):6–17.PubMedGoogle Scholar
  39. 39.
    Younes NA, Shafagoj Y, Khatib F, Ababneh M. Laboratory screening for hyperparathyroidism. Clin Chim Acta. 2005; 353(1–2):1–12.PubMedGoogle Scholar
  40. 40.
    Palazzo FF, Delbridge LW. Minimal-access/minimally invasive parathyroidectomy for primary hyperparathyroidism. Surg Clin North Am. 2004; 84(3):717–734.PubMedGoogle Scholar
  41. 41.
    Pietila K, Morsky P, Pasternack A, Mustonen J, Koivula T. Intact parathyroid hormone, ionized calcium and calcium infusion test in the evaluation of hyperparathyroidism in chronic renal failure. Nephron. 1987;47(4):284–289.PubMedGoogle Scholar
  42. 42.
    Iwasaki Y, Mutsuga N, Yamamori E, Kakita A, Oiso Y, Imai T, Funahashi H, Tanaka Y, Kondo K, Nakashima N. Sodium bicarbonate infusion test: a new method for evaluating parathyroid function. Endocr J. 2003; 50(5):545–551.PubMedGoogle Scholar
  43. 43.
    Nemeth EF. Calcimimetic and calcilytic drugs: just for parathyroid cells? Cell Calcium. 2004; 35(3):283–289.PubMedGoogle Scholar
  44. 44.
    Davies M, Fraser WD, Hosking DJ. The management of primary hyperparathyroidism. Clin Endocrinol (Oxf). 2002; 57(2):145–155.Google Scholar
  45. 45.
    de Francisco AL. Secondary hyperparathyroidism: review of the disease and its treatment. Clin Ther. 2004; 26(12):1976–1993.PubMedGoogle Scholar
  46. 46.
    Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001; 4:477–501.Google Scholar
  47. 47.
    Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int Suppl. 2005; (94):S120–S127.Google Scholar
  48. 48.
    Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf). 2005; 62(3):265–281.Google Scholar
  49. 49.
    Schlosser K, Zielke A, Rothmund M. Medical and surgical treatment for secondary and tertiary hyperparathyroidism. Scand J Surg. 2004; 93(4):288–297.PubMedGoogle Scholar
  50. 50.
    Fernandez-Cruz L, Puig-Domingo M, Halperin I, Sesmilo G. Pheochromocytoma. Scand J Surg. 2004; 93(4):302–309.PubMedGoogle Scholar
  51. 51.
    Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, Brouwers FM, Pacak K. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem. 2005; 51(4):735–744.PubMedGoogle Scholar
  52. 52.
    Goldstein DS, Eisenhofer G, Flynn JA, Wand G, Pacak K. Diagnosis and localization of pheochromocytoma. Hypertension. 2004; 43(5):907–910.PubMedGoogle Scholar
  53. 53.
    Pacak K, Ilias I, Adams KT, Eisenhofer G. Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour. J Intern Med. 2005; 257(1):60–68.PubMedGoogle Scholar
  54. 54.
    Davies RA, Patt NL, Sole MJ. Localization of pheochromocytoma by selective venous catheterization and assay of plasma catecholamines. Can Med Assoc J. 1979; 120(5):539–542.PubMedGoogle Scholar
  55. 55.
    Grossman E, Goldstein DS, Hoffman A, Keiser HR. Glucagon and clonidine testing in the diagnosis of pheochromocytoma. Hypertension. 1991; 17(6 Pt 1):733–741.PubMedGoogle Scholar
  56. 56.
    Chavez-Rodriguez J, Pasieka JL. Adrenal lesions assessed in the era of laparoscopic adrenalectomy: a modern day series. Am J Surg. 2005; 189(5):581–585.PubMedGoogle Scholar
  57. 57.
    Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005; 17(1):7–13.PubMedGoogle Scholar
  58. 58.
    NIH state-of-the-science statement on management of the clinically inapparent adrenal mass („incidentaloma“). NIH Consens State Sci Statements. 2002; 19(2):1–25.Google Scholar
  59. 59.
    Leowattana W. DHEAS as a new diagnostic tool. Clin Chim Acta. 2004; 341(1–2):1–15.PubMedGoogle Scholar
  60. 60.
    Beauregard C, Dickstein G, Lacroix A. Classic and recent etiologies of Cushing’s syndrome: diagnosis and therapy. Treat Endocrinol. 2002; 1(2):79–94.PubMedGoogle Scholar
  61. 61.
    NewelI-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev. 1998; 19(5):647–672.PubMedGoogle Scholar
  62. 62.
    Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G, Kirschner MA. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000; 88(4):711–736.PubMedGoogle Scholar
  63. 63.
    Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004; 25(2):309–340.PubMedGoogle Scholar
  64. 64.
    Sonino N, Boscaro M, Fallo F. Pharmacologic management of Cushing syndrome: new targets for therapy. Treat Endocrinol. 2005; 4(2):87–94.PubMedGoogle Scholar
  65. 65.
    Marzotti S, Falorni A. Addison’s disease. Autoimmunity. 2004; 37(4):333–336.PubMedGoogle Scholar
  66. 66.
    Ellacott KL, Cone RD. The central melanocortin system and the integration of short-and long-term regulators of energy homeostasis. Recent Prog Horm Res. 2004; 59:395–408.PubMedGoogle Scholar
  67. 67.
    Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev. 2002; 23(3):327–364.PubMedGoogle Scholar
  68. 68.
    Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med. 2003; 139(3):194–204.PubMedGoogle Scholar
  69. 69.
    Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med. 2004; 350(20):2068–2079.PubMedGoogle Scholar
  70. 70.
    Kaplan NM. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens. 2004; 22(5):863–869PubMedGoogle Scholar
  71. 71.
    Plouin PF, Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits? Eur J Endocrinol. 2004; 151(3)305–308.PubMedGoogle Scholar
  72. 72.
    Miedlich S, Lohmann T, Schneyer U, Lamesch P, Paschke R. Familial isolated primary hyperparathyroidism—a multiple endocrine neoplasia type 1 variant? EurJ Endocrinol. 2001; 145(2):155–160.Google Scholar
  73. 73.
    Reincke M, Seiler L, Rump LC Normokaliämischer primärer Hyperaldosteronismus. Dtsch Äbl 2003; 100:184–190.Google Scholar
  74. 74.
    Croom KF, Perry CM. Eplerenone: a review of its use in essential hypertension. Am J Cardiovasc Drugs. 2005; 5(1):51–69.PubMedGoogle Scholar
  75. 75.
    Wiegratz I, Kuhl H. Managing cutaneous manifestations of hyperandrogenic disorders: the role of oral contraceptives. Treat Endocrinol. 2002; 1(6):372–386.PubMedGoogle Scholar
  76. 76.
    Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005; 352(12):1223–1236PubMedGoogle Scholar
  77. 77.
    Burger HG. Androgen production in women. Fertil Steril. 2002; 77Suppl 4:S3–S5.PubMedGoogle Scholar
  78. 78.
    Aron DC, Howlett TA. Pituitary incidentalomas. Endocrinol Metab Clin North Am. 2000; 29(1):205–221PubMedGoogle Scholar
  79. 79.
    Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005; 90(5):3089–3099.PubMedGoogle Scholar
  80. 80.
    Kelestimur F. Sheehan’s syndrome. Pituitary. 2003; 6(4):181–188.PubMedGoogle Scholar
  81. 81.
    Dickstein G. The assessment of the hypothalamo-pituitary-adrenal axis in pituitary disease: are there short cuts? J Endocrinol Invest. 2003; 26(7 Suppl):25–30.PubMedGoogle Scholar
  82. 82.
    Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treat Endocrinol. 2003; 2(1):23–32.PubMedGoogle Scholar
  83. 83.
    Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003; 349(21):2035–2041.PubMedGoogle Scholar
  84. 84.
    Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary. 2002; 5(2):55–65.PubMedGoogle Scholar
  85. 85.
    Grottoli S, Gasco V, Ragazzoni F, Ghigo E. Hormonal diagnosis of GH hypersecretory states. J Endocrinol Invest. 2003; 26(10 Suppl):27–35.PubMedGoogle Scholar
  86. 86.
    Arafah BM, Nasrallah MR Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer. 2001; 8(4):287–305.PubMedGoogle Scholar
  87. 87.
    Müller EE, Rigamonti AE, Cella SG. Mechanisms of action of GH. J Endocrinol Invest. 2003; 26(10 Suppl):2–15.PubMedGoogle Scholar
  88. 88.
    Wass JA. Dynamic testing in the diagnosis and follow-up of patients with acromegaly. J Endocrinol Invest. 2003; 26(7 Suppl):48–53.PubMedGoogle Scholar
  89. 89.
    Grottoli S, Gasco V, Ragazzoni F, Ghigo E. Hormonal diagnosis of GH hypersecretory states. J Endocrinol Invest. 2003; 26(10 Suppl):27–35.PubMedGoogle Scholar
  90. 90.
    Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2003; 88(12):5593–5602.PubMedGoogle Scholar
  91. 91.
    Sudhakar N, Ray A, Vafidis JA. Complications after trans-sphenoidal surgery: our experience and a review of the literature. Br J Neurosurg. 2004; 18(5):507–512.PubMedGoogle Scholar
  92. 92.
    Koriyama N, Nakazaki M, Hashiguchi H, Aso K, Ikeda Y, Kimura T, Eto H, Hirano H, Nakano S, Tei C. Thyrotropin-producing pituitary adenoma associated with Graves’disease. Eur J Endocrinol. 2004; 151(5):587–594.PubMedGoogle Scholar
  93. 93.
    Ball SG, Barber T, Baylis PH. Tests of posterior pituitary function. J Endocrinol Invest. 2003; 26(7 Suppl):15–24PubMedGoogle Scholar
  94. 94.
    Arafah BM. Medical management of hypopituitarism in patients with pituitary adenomas. Pituitary. 2002; 5(2):109–117.PubMedGoogle Scholar
  95. 95.
    Verbalis JG. Management of disorders of water metabolism in patients with pituitary tumors Pituitary. 2002; 5(2):119–132.PubMedGoogle Scholar
  96. 96.
    Maghnie M. Diabetes insipidus. Horm Res. 2003; 59Suppl 1:42–54.PubMedGoogle Scholar
  97. 97.
    Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf. 1999; 21(6):449–456.PubMedGoogle Scholar
  98. 98.
    Ball SG, Barber T, Baylis PH. Tests of posterior pituitary function. J Endocrinol Invest. 2003; 26(7 Suppl):15–24.PubMedGoogle Scholar
  99. 99.
    Vokes TJ, Robertson GL. Disorders of antidiuretic hormone. Endocrinol Metab Clin North Am. 1988; 17(2):281–299.PubMedGoogle Scholar
  100. 100.
    Vachharajani TJ, Zaman F, Abreo KD. Hyponatremia in critically ill patients. J Intensive Care Med. 2003; 18(1):3–8.PubMedGoogle Scholar
  101. 101.
    Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol. 2003; 35(11):1495–1499.PubMedGoogle Scholar
  102. 102.
    Seibel MJ. Biochemical markers of bone metabolism in the assessment of osteoporosis: useful or not? J Endocrinol Invest. 2003; 26(5):464–471.PubMedGoogle Scholar
  103. 103.
    Christodoulou C, Cooper C. What is osteoporosis? Postgrad Med J. 2003; 79(929):133–138.PubMedGoogle Scholar
  104. 104.
    Inaba M. Secondary osteoporosis: thyrotoxicosis, rheumatoid arthritis, and diabetes mellitus. J Bone Miner Metab. 2004; 22(4):287–292.PubMedGoogle Scholar
  105. 105.
    Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int. 2004; 74(1):103–106.PubMedGoogle Scholar
  106. 106.
    Crandall C. Laboratory workup for osteoporosis. Which tests are most cost-effective? Postgrad Med. 2003; 114(3):35–38, 41–4.PubMedGoogle Scholar
  107. 107.
    Obermayer-Pietsch BM, Bonelli CM, Walter DE, Kuhn RJ, Fahrleitner-Pammer A, Berghold A, Goessler W, Stepan V, Dobnig H, Leb G, Renner W. Genetic predisposition for adult lactose intolerance and relation to diet, bone density, and bone fractures J Bone Miner Res. 2004; 19(1):42–47.PubMedGoogle Scholar
  108. 108.
    Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther. 2005; 27(1):1–11.PubMedGoogle Scholar
  109. 109.
    Stepan JJ. Clinical utility of bone markers in the evaluation and follow-up of osteoporotic patients: why are the markers poorly accepted by clinicians? J Endocrinol Invest. 2003; 26(5):458–463.PubMedGoogle Scholar
  110. 110.
    Hammett-Stabler CA. The use of biochemical markers in osteoporosis. Clin Lab Med. 2004; 24(1):175–197.PubMedGoogle Scholar
  111. 111.
    Bielesz B, Klaushofer K, Oberbauer R. Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone. 2004; 35(6):1229–1239.PubMedGoogle Scholar
  112. 112.
    Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004; 80(6 Suppl):1678S–1688SPubMedGoogle Scholar
  113. 113.
    Malluche HH, Langub MC, Monier-Faugere MC. The role of bone biopsy in clinical practice and research. Kidney Int Suppl. 1999; 73:S20–S25.PubMedGoogle Scholar
  114. 114.
    Roodman GD, Windle JJ. Paget disease of bone. Clin Invest. 2005;115(2):200–208.Google Scholar
  115. 115.
    Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab. 2003;88(11):5059–5075.PubMedGoogle Scholar
  116. 116.
    Bukulmez O, Arici A. Assessment of ovarian reserve. Curr Opin Obstet Gynecol. 2004;16(3):231–237.PubMedGoogle Scholar
  117. 117.
    Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005; 52(12):1223–1236.Google Scholar
  118. 118.
    McCann SM, Karanth S, Mastronardi CA, Dees WL, Childs G, Miller B, Sower S, Yu WH. Control of gonadotropin secretion by follicle-stimulating hormone-releasing factor, luteinizing hormone-releasing hormone, and leptin. Arch Med Res. 2001; 2(6):476–485.Google Scholar
  119. 119.
    Moretti C, Toscano V. Dynamic evaluation of ovarian reserve and abnormal androgen excess in women. J Endocrinol Invest. 2003; 6(7 Suppl):114–123.Google Scholar
  120. 120.
    McLachlan RI, Allan CA. Defining the prevalence and incidence of androgen deficiency in aging men: where are the goal posts? J Clin Endocrinol Metab. 2004; 9(12):5916–5919.Google Scholar
  121. 121.
    Liu PY, Swerdloff RS, Veldhuis JD. Clinical review 171:The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab. 2004; 9(10):4789–4796.Google Scholar
  122. 122.
    Byrne M, Nieschlag E. Testosterone replacement therapy in male hypogonadism. J Endocrinol Invest. 2003; 6(5):481–489.Google Scholar
  123. 123.
    Badenhoop K, Boehm BO. Genetic susceptibility and immunological synapse in type 1 diabetes and thyroid autoimmune disease. Exp Clin Endocrinol Diabetes. 2004; 12(8):407–415Google Scholar
  124. 124.
    Thakker RV. Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium. 2004; 5(3):275–282.Google Scholar
  125. 125.
    Miedlich S, Krohn K, Paschke R. Update on genetic and clinical aspects of primary hyperparathyroidism. Clin Endocrinol (Oxf). 2003; 59(5):539–554.Google Scholar
  126. 126.
    Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005 May;5(5):367–375.Google Scholar
  127. 127.
    Stratakis CA, Kirschner LS. Clinical and genetic analysis of primary bilateral adrenal diseases (micro-and macronodular disease) leading to Cushing syndrome. Horm Metab Res. 1998; 30(6–7):456–463.PubMedGoogle Scholar
  128. 128.
    Connell JM, Fraser R, MacKenzie SM, Friel EC, Ingram MC, Holloway CD, Davies E. The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation. Mol Cell Endocrinol. 2004; 217(1–2):243–247.PubMedGoogle Scholar
  129. 129.
    Keavney B, Mayosi B, Gaukrodger N, Imrie H, Baker M, Fraser R, Ingram M, Watkins H, Farrall M, Davies E, Connell J. Genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor (11-deoxycortisol) urinary metabolite excretion. J Clin Endocrinol Metab. 2005; 90(2):1072–1077.PubMedGoogle Scholar
  130. 130.
    Trakakis E, Laggas D, Salamalekis E, Creatsas G. 21-Hydroxylase deficiency: from molecular genetics to clinical presentation. J Endocrinol Invest. 2005; 28(2): 187–192.PubMedGoogle Scholar
  131. 131.
    Drange MR, Melmed S. Molecular pathogenesis of acromegaly. Pituitary. 1999;2(1): 43–50.PubMedGoogle Scholar
  132. 132.
    Namihira H, Sato M, Murao K, Cao WM, Matsubara S, Imachi H, Niimi M, Dobashi H, Wong NC, Ishida T. The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. J Mol Endocrinol. 2002; 29(3):297–304.PubMedGoogle Scholar
  133. 133.
    Ralston SH. Genetic determinants of osteoporosis. Curr Opin Rheumatol. 2005; 17(4):475–479.PubMedGoogle Scholar
  134. 134.
    Andrew T, Antioniades L, Scurrah KJ, Macgregor AJ, Spector TD. Risk of wrist fracture in women is heritable and is influenced by genes that are largely independent of those influencing BMD. J Bone Miner Res. 2005; 20(1):67–74.PubMedGoogle Scholar
  135. 135.
    Ioannidis JP, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, Langdahl B, van Meurs JB, Mosekilde L, Scollen S, Albagha OM, Bustamante M, Carey AH, Dunning AM, Enjuanes A, van Leeuwen JP, Mavilia C, Masi L, McGuigan FE, Nogues X, Pols HA, Reid DM, Schuit SC, Sherlock RE, Uitterlinden AG; GENOMOS Study. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA. 2004; 292(17):2105–2114.PubMedGoogle Scholar
  136. 136.
    Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005; 26(2):251–282.PubMedGoogle Scholar
  137. 137.
    Zinn AR, Ramos P, Elder FF, Kowal K, Samango-Sprouse C, Ross JL. Androgen receptor CAGn repeat length influences phenotype of 47, XXY (Klinefelter) syndrome. J Clin Endocrinol Metab. 2005;90(9):5041–5046.PubMedGoogle Scholar
  138. 138.
    Glaser B. Genetic analysis of complex disease — a roadmap to understand or a colossal waste of money. Pediatr Endocrinal Rev 2010; 7(3):258–265.Google Scholar
  139. 139.
    Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension. Nat Rev Endocrinol. 2010;6(2):83–93.PubMedGoogle Scholar
  140. 140.
    Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, Obermayer-Pietsch B. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009;161(4):575–582.PubMedGoogle Scholar
  141. 141.
    Rivadeneira F, Styrkársdottir U, Estrada K, Halldórsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdottir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP, Uitterlinden AG; Genetic Factors for Osteoporosis (GEFOS) Consortium. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009;41(11):1199–1206.PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2011

Authors and Affiliations

  • B. Obermayer-Pietsch
    • 1
  1. 1.Medizinische Universität GrazUniversitätsklinik für Innere Medizin Klinische Abteilung für Endokrinologie & NuklearmedizinGraz

Personalised recommendations

Cite chapter

Buy options